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Abstract
Background: A novel avian influenza A (H7N9) virus emerged in eastern China in February 2013. 413 confirmed
human cases, including 157 deaths, have been recorded as of July 31, 2014.
Methods: Clinical specimens, including throat swabs, sputum or tracheal aspirates, etc., were obtained from patients
exhibiting influenza-like illness (ILIs), especially from those having pneumonia and a history of occupational exposure
to poultry and wild birds. RNA was extracted from these samples and a multiplex one-step real-time RT-PCR assay was
developed to specifically detect the influenza A virus (FluA). PCR primers targeted the conserved M and Rnase P (RP)
genes, as well as the hemagglutinin and neuraminidase genes of the H7N9 virus.
Results: The multiplex assay specifically detected the avian H7N9 virus, and no cross-reaction with other common
respiratory pathogens was observed. The detection limit of the assay was approximately 0.05 50% tissue culture
infective doses (TCID50), or 100 copies per reaction. Positive detection of the H7N9 virus in sputum/tracheal
aspirates was higher than in throat swabs during the surveillance of patients with ILIs. Additionally, detection
of the matrix (M) and Rnase P genes aided in the determination of the novel avian H7N9 virus and ensured the quality
of the clinical samples.
Conclusions: These results demonstrate that the multiplex assay detected the novel avian H7N9 virus with high
specificity and sensitivity, which is essential for the early diagnosis and treatment of infected patients.
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Background
The influenza A virus (FluA) is a negative-sense, single-
stranded RNA virus belonging to the family Orthomyx-
oviridae. FluA is further classified on the basis of two
surface glycoproteins, hemagglutinin (H) and neuramin-
idase (N) [1,2]. All subtypes of FluA comprise various
combinations of the H and N glycoproteins. Sixteen H
subtypes (H1-H16) and nine N subtypes (N1-N9) have
been characterized in avian species, while the H17N10
subtype is found in bats [3,4]. Most subtypes of FluA virus
such as H5 and H7 subtypes are not pathogenic in
poultry, but outbreaks in poultry and wild birds are corre-
lated with the highly virulent FluA virus, which can cause
severe economic losses owing to massive numbers of
deaths of domestic poultry [4-6].
Human infections are generally associated with the H1,
H2, and H3 subtypes, although sporadic cases or out-
breaks of avian FluA subtypes H5N1 [3], H7N2 [5], H7N3
[5], H7N7 [6], H10N8 [7], H10N7 [8], and H9N2 [9] have
resulted from direct transmissions from domestic poultry
and wild birds to humans. Most patients infected with
these subtypes exhibit mild symptoms, such as conjunctiv-
itis and acute upper respiratory tract infections associated
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with fever and sore throat, with or without gastrointestinal
symptoms. However, the H5N1 virus exhibits a high mor-
tality rate of over 50%, the H7N7 virus has caused one fa-
tality, and three deaths have resulted from the H10N8
virus [3,5,6].
The avian influenza A (H7N9) virus has been found in
poultry and birds, although no human infections have
been documented, and its pathogenicity was found to be
low in previous studies [4]. Since February 2013, a novel,
reassortant avian influenza A (H7N9) virus associated
with human deaths has emerged in eastern China [10,11].
Up to February 28, 2014, this novel, highly virulent H7N9
virus for humans has infected over 381 patients who pre-
sented with influenza-like illness (ILI) and severe acquired
pneumonia, resulting in 118 deaths. It will be a challenge
to control the H7N9 outbreak in humans before it spreads
further. Currently, sporadic cases, but no evident out-
breaks, of this novel virus have been documented in wild
birds and poultry, and there is some limited evidence of
human-to-human transmission during unprotected expos-
ure [12], and there are no vaccines for humans.
Thus, early detection and isolation of suspected pa-
tients are the most effective measures to control and
prevent further transmission of the virus. Here, we re-
port a multiplex real-time RT-PCR assay allowing the
simultaneous detection and discrimination of universal
FluA strains and the novel H7N9 subtype in a single test
tube. The results showed that the sensitivity and specifi-
city of this assay was comparable to a protocol recom-
mended by the World Health Organization (WHO).
Methods
Primer and probe design
Primers and probes were designed to correspond to con-
served regions of the FluA matrix (M) gene segment. The
primers/probes for the novel H7N9 strain were designed
to detect subtype-specific H and N gene segments, and the
Rnase P gene (RP) served as an internal control to monitor
the quality of the clinical specimens. These primers/probes
were designed according to the Influenza Primer Design
Resource and primers/probes recommended by the WHO
protocol were listed in Table 1 [13].
Clinical specimens and patients
According to diagnostic criteria of China for the detec-
tion of avian influenza A(H7N9) virus highly virulent in
humans, patients with acute respiratory infections with
influenza-like illness (ILIs), especially those having pneu-
monia and a history of occupational exposure to poultry
and wild birds, were examined by the Infection Depart-
ment of the First Affiliated Hospital of the College of
Medicine of Zhejiang University. Clinical specimens, in-
cluding throat swabs, nasal aspirates and washes, and spu-
tum specimens, were collected beginning in April 2013.
Moreover, clinical specimens were also collected from pa-
tients with confirmed H7N9 viral infections. All specimens
were stored at −80°C. Specimens were tested for the pres-
ence of FluA and the novel H7N9 subtype using a real-
time RT-PCR assay, and highly virulent avian influenza A
(H7N9) virus and other common respiratory pathogens
were cultured in the State Key Laboratory for Diagnosis
and Treatment of Infectious Diseases. According to the
Declaration of Helsinki (1964), informed consents for par-
ticipation were obtained from the participants or guardians
of the patients, and the Medical Ethical Committee of our
hospital approved this study.
Viral RNA extraction
RNA from viral cultures of three novel human H7N9 vi-
ruses, three human novel H1N1 viruses, five seasonal hu-
man H1N1 viruses, five seasonal human H3N2 viruses,
three human influenza B viruses, 83 specimens from pa-
tients without ILI, and 1,011 specimens from patients
with ILI was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol.
Multiplex real-time RT-PCR assay
The multiplex one-step real-time RT-PCR assays were
carried out using the One Step PrimeScript® RT-PCR Kit
(Perfect Real Time) (Takara, China). In brief, 1.0 μl of
20 μM FluA, H7, N9 and RP primers, 0.5 μl of the corre-
sponding probes. 5 μl of RNA, 25 μl of 2× One Step
RT-PCR buffer, 2 μl of Ex Taq HS Polymerase, 2 μl
of PrimeScript RT Enzyme Mix and an appropriate vol-
ume of Rnase-free distilled water (dH2O) were combined
in a 50 μl reaction volume. The thermal cycles were per-
formed on an ABI 7500 real-time PCR system (Applied
Biosystems, Foster city, CA) under the following condi-
tions: 30 min at 50°C for reverse transcription; 5 min at
95°C, then 40 cycles at 95°C for 15 s and 55°C for 45 s for
PCR amplification. The PCR results were determined if
the quality controls work. First, the specimen is positive if
Ct value is ≤38.0 with appropriate results. Second, the spe-
cimen is negative if the Ct value is undetectable. Third,
the specimen with a Ct > 38 is suggested to be repeated,
the specimen is considered positive if the repeat result is
the same as before, conversely the specimen is considered
negative if the repeat result is undetectable.
Viral culture
Madin-Darby canine kidney (MDCK) cells were used to
isolate the novel avian influenza A (H7N9) virus using
standard methods in a biosafety level three (BSL-3) la-
boratory. MDCK cells were inoculated with fresh clinical
specimens. When the cytopathogenic effect (CPE) of the
virus was observed, cells were harvested and tested for
the novel H7N9 virus by PCR assay of WHO protocol.
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The harvested viruses were clarified by low-speed centri-
fugation (8000 g/min) and used as viral stocks.
Sensitivity and specificity
Titers of the novel H7N9 viruses were calculated by de-
termining the 50% tissue culture infective dose (TCID50).
The sensitivity was determined per reaction using a real-
time RT-PCR assay of serial 10-fold dilutions of the
novel H7N9 viruses, starting with 5 × 103 TCID50 per reac-
tion. In addition, serial dilutions of the RNA transcripts,
ranging from 1 × 106 to 1 × 101 copies per reaction were
also used to assess the sensitivity of the assay. RNA was
transcribed in vitro using a recombinant pGEM®-Easy plas-
mid (Promega, Shanghai, China) and the RiboMAXTM
Large Scale RNA Production System-SP6 (Promega) ac-
cording to the manufacturer’s protocol, as described in
previous reports [1,2]. Moreover, the detection limits
of the multiplex real-time RT-PCR assay were directly
compared to a widely used real-time RT-PCR assay proto-
col that is recommended by the WHO.
The specificity of the assay was assessed for the novel
avian influenza A H7N9 viruses and 21 other respiratory
pathogens and commensal organisms: human seasonal
FluA (H1N1 and H3N2 viruses), pandemic H1N1-2009 in-
fluenza A virus, influenza B virus, avian H5N1, avian H9N2,
avian H5N3, respiratory syncytial virus (types A and B),
human rhinovirus, Mycoplasma pneumoniae, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, Staphylococcus aureus, Candida albicans,
Neisseria meningitides, human parainfluenza virus (types 1
and 2), human adenovirus, and human coronavirus (OC43).
Clinical sensitivity and specificity
One hundred and thirty throat swabs or sputum speci-
mens were tested at the Center for Clinical Laboratory
of the First Affiliated Hospital of the Medical School of
Table 1 Primers and probes designed and used in this study
Set Primers and probes Sequences (5′→ 3′) Targeted genes Location (bp) GenBank accession no.
Designed and used in this study
FluA FluA forward GGARTGGMTAAAGACAAGACCAATC 129-153
FluA reverse GGCRTTYTGGACAAASCGTCTAC Matrix protein 227-249 KC885959.1
FluA probe ROX- AGTCCTCGCTCACTGGGCACGGT-BHQ2 199-221
H7 H7 forward GAGGCRATGCAAAATAGAATACAGAT 1510-1535
H7 reverse CCGAAGCTAAACCARAGTATCACA Hemagglutinin 1569-1592 KC885956.1
H7 probe FAM- ACCCRGTCAAACTAAGCAGCGGYTAYAA-BHQ1 1538-1565
N9 N9 forward GCCCTGATAAGCTGGCCACT 472-491
N9 reverse ACTAGTACTTGACCAMCCAATGCA Neuraminidase 529-552 KC885958.1
N9 probe HEX- TCACCRCCCACAGTRTACAAYAGCA-BHQ1 496-520
RP RP forward AGATTTGGACCTGCGAGCG 50-68
RP reverse GAGCGGCTGTCTCCACAAGT Ribonuclease P 71-93 NM_006413.4
RP probe CY5- TTCTGACCTGAAGGCTCTGCGCG-BHQ2 95-114
Designed in the World Health Organization (WHO) protocol and used in this study
FluA InfA Forward GACCRATCCTGTCACCTCTGAC 146-167
InfA Reverse AGGGCATTYTGGACAAAKCGTCTA Matrix protein 228-251
InfA Probe FAM-TGCAGTCCTCGCTCACTGGGCACG-BHQ1 201-224
H7 CNIC-H7F GGTTTTTTCTTGTATTTTTATATGACTTAG 468-490
CNIC-H7R GGTTTTTTCTTGTATTTTTATATGACTTAG Hemagglutinin 521-550
CNIC-H7P FAM-AGATAATGCTGCATTCCCGCAGATG-BHQ1 495-519
N9 CNIC-N9F TGGCAATGACACACACTAGTCAGT 929-952
CNIC-N9R ATTACCTGGATAAGGGTCGTTACACT Neuraminidase 1010-1035
CNIC-N9P FAM- AGACAATCCCCGACCGAATGACCC -BHQ1 975-998
Rnase P Rnase P Forward AGATTTGGACCTGCGAGCG 50-68
Rnase P Reverse GAGCGGCTGTCTCCACAAGT Ribonuclease P 71-93
Rnase P Probe FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ1 95-114
The 6th base of the FluA reverse primer was changed from “G” to “A”, the 3rd base of the H7 reverse primer was changed from “C” to “T”, and the 2nd and 23rd
bases of the N9 forward primer and the 19th base of the N9 reverse primer were changed from “T” to “G”, “T” to “G”, “A” to “G”, with respect to the novel H7N9
sequences, in the WHO-recommended primers.
Fan et al. BMC Infectious Diseases 2014, 14:541 Page 3 of 9
http://www.biomedcentral.com/1471-2334/14/541
Zhejiang University and the State Key Laboratory for
Diagnosis and Treatment of Infectious Diseases. These
specimens were determined to be positive for FluA and the
H7N9 subtype specifically by tissue culture, and each sam-
ple was blindly tested and compared using the multiplex
real-time RT-PCR and the WHO-recommended real-time
RT-PCR assays. Moreover, tissue culture results were used
as the true result for sensitivity and specificity calculations.
Evaluation of the multiplex real-time RT-PCR using clinical
specimens
One thousand and eleven clinical respiratory samples,
including throat swabs, sputum or lower respiratory
tract specimens from patients with acute respiratory in-
fections acquired since April 2013 were tested for FluA
and the novel H7N9 viruses using the multiplex real-
time RT-PCR at the Center for Clinical Laboratory of
the First Affiliated Hospital of the College of Medicine
of Zhejiang University. Specimens from patients with
confirmed H7N9 infections were tested to determine the
persistence and distribution of the H7N9 virus and to
evaluate the diagnostic abilities of the multiplex and
WHO-recommended real-time RT-PCR assays during
hospital stays.
To assess the validity of viral RNA amplification by
the multiplex real-time RT-PCR assay, the partially amp-
lified DNA products of samples testing positive by the
multiplex real-time RT-PCR assay were selected ran-
domly and cloned into the pMD18T vector (Takara,
Japan). Plasmids were transformed into Escherichia coli
and their sequences were verified by Sangon Biotech
Co., Ltd. (Shanghai, China).
Ethics statement
The protocol was approved by the Ethics Committee of
the First Affiliated Hospital, School of Medicine, Zhejiang
University.
Results
Design of specific primers and probes for the novel
influenza A (H7N9) virus
In the WHO protocol, the novel H7N9 virus was detected
using a real-time RT-PCR assay that requires four individ-
ual tubes, which increases the experimental procedures
and expenses. Therefore, using novel H7N9 sequences
submitted to the National Center for Biotechnology Infor-
mation (NCBI) database, we designed a new set of primers
and probes to specifically detect the novel H7N9 virus by a
multiplex real-time RT-PCR assay in one reaction tube
(Table 1). As recommend by the WHO protocol, the
primers and probes were designed for the universal detec-
tion of FluA, and the primers and probes for RP were used
as an internal control to evaluate the quality of the clin-
ical specimens. The primers and probes for the H7 and
N9 genes were designed within certain regions of the
hemagglutinin (HA) and neuraminidase (NA) genes that are
relatively conserved among all H7N9 subtypes, thus allow-
ing the detection of all human and avian H7N9 viruses. As
expected, viral RNA samples extracted from novel human
H7N9 isolates (A/Zhejiang/DTID-ZJU01/2013) were de-
tected by the multiplex assay (data not shown).
Sensitivity and specificity of multiplex real-time RT-PCR
assay for the novel H7N9 virus
In the multiplex real-time RT-PCR assay for detecting
novel H7N9 viruses, the sensitivities of the FluA, H7,
and N9 primer and probe sets were all 5 × 10−2 TCID50
per reaction, and the detection limits for the RNA tran-
scripts were all 1 × 102 copies/per reaction (Table 2).
Interestingly, the same detection limits were found for
FluA, CNIC-H7 and CNIC-N9 assays in a previous study
[13,14]. Similarly, the specificity of the multiplex assay
was evaluated individually using H7N9 virus culture and
RNA transcripts. With respect to specificity, the multi-
plex assay detected the novel H7N9 virus, the FluA
(H1N1 and H3N2) viruses and the novel influenza A
H1N1 (2009) virus, and no cross-reactions were observed
with the panel comprising 21 other respiratory pathogens
or commensals. The specificity of the multiplex assay was
similar to that of the WHO-recommended assay. Thus,
these results indicate that the multiplex assay designed in
this study is sufficiently sensitive and specific to be used to
detect the novel H7N9 virus. Experiments were repeated
at least three times.
Clinical sensitivity and specificity of multiplex real-time
RT-PCR assay
Fifteen positive specimens out of 130 clinical specimens
were positively identified by the multiplex and WHO-
recommended real-time RT-PCR assays; all were FluA,
with four novel H7N9 viruses and 11 other FluA subtypes.
In addition, these 11 FluA subtypes consisted of three
pandemic H1N1-2009 influenza A viruses, seven seasonal
H3N2 viruses, and one seasonal H1N1 virus, and were
certified by other real-time RT-PCR assays in previous
reports [1,2]. In contrast, tissue culture methods detected
only 13 positive FluA viruses out of the 130 clinical speci-
mens. Of the two samples that tested positive with the multi-
plex assay and negative by tissue culture, one contained
Table 2 Multiplex PCR for detecting the novel H7N9 virus
(TCID50) and RNA transcripts (copies)
Name
Copies/per reaction TCID50/per reaction
Multiplex WHO Multiplex WHO
Flu A 1 × 102 1 × 102 5 × 10−2 5 × 10−2
H7 1 × 102 1 × 102 5 × 10−2 5 × 10−2
N9 1 × 102 1 × 102 5 × 10−2 5 × 10−2
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one pandemic H1N1-2009 influenza A virus and the other
contained a seasonal H3N2 virus; these two indeterminate
tissue culture results were subsequently confirmed to be
positive by genomic sequence analysis and were excluded
from the sensitivity and specificity calculations. Interest-
ingly, four specimens that tested positive for the novel
H7N9 virus were uniformly detected by all of the assays.
In comparison to the tissue culture method, the multiplex
assay and WHO-recommended protocol had the same
sensitivity (100%) and specificity (98.3%) for FluA, and the
same sensitivities and specificities for the H7 (100%) and
N9 (100%) genes in the clinical specimen (Table 3). The
cycle threshold (Ct) values, defined as the number of cycles
required for the fluorescent signal to cross the detection
threshold, of FluA and the H7 and N9 genes, and RP gene
of the novel H7N9 virus did not obviously differ between
the multiplex assay and WHO-recommended protocol
(Table 4). These tests by PCR assay were repeated at least
three times.
Detecting clinical specimens using multiplex real-time
RT-PCR assay
To further demonstrate assay sensitivity and specificity,
1,011 new specimens were tested in parallel using the
multiplex real-time RT-PCR and the WHO-recommended
real-time RT-PCR protocol. The results showed that, using
the multiplex assay, 192 specimens tested positive for
FluA, including 35 specimens that were positive for the
H7N9 virus. No co-infections with viruses were found
in the multiplex tests, 819 samples tested negative for
FluA, and the Ct values of RP gene were all positive
with 18.5 ~ 29.6 for 1,011 clinical specimens (Table 5).
In comparison, the Ct values of RP gene were also all posi-
tive with 18.6 ~ 29.8 in 1,011 samples, 192 specimens
tested positive for FluA using the WHO protocol. With
respect to the H7 gene, both assays identified 35 positive
samples. However, the multiplex assay also detected 35
positive samples with respect to the N9 gene, while the
WHO protocol only detected 32 positives, and the Ct
value of N9 gene in three patients was high with 36 ~ 38
indicating low titres of the H7N9 virus. In an addition, to
demonstrate whether the three N9 samples that differed
between the two assays were positive or negative, firstly,
we amplified DNA products using N9-specific primers,
and DNA sequencing of the cloned products revealed that
these three samples were confirmed to be positive. Sec-
ondly, the sputum of the three cases was individually
re-collected and re-detected again, and the Ct values
of the three cases in N9 gene were all less than 34. In the
three cases, the Ct values of RP gene were individually
27.5 ~ 28.5 (the early samples) and 26.8 ~ 28.5 (the late
samples) in the twice samples. Moreover, 35 patients with
confirmed novel H7N9 virus infections accepted hospital
treatments and their clinical specimens (including throat
swab [135 specimens], sputum or tracheal aspirates [160
specimens], etc.) were tested for the presence and distri-
bution of the H7N9 virus by the multiplex and WHO-
recommend real-time RT-PCR assays every day following
admission, which contributed to the evaluation of thera-
peutic treatments received by the patients. Eight fecal
samples from the 35 patients tested positive for the H7N9
virus using the multiplex assay, while only seven tested
positive using the WHO-recommend assay. No positive
results for the H7N9 virus were found in blood (35 speci-
mens), urine (30 specimens), cerebrospinal fluid (one spe-
cimen), pleural fluid (one specimen) and bone marrow
specimens (two specimens). The results of the throat
swabs and sputum or tracheal aspirates specimens from
35 patients with H7N9 infections were shown in Figure 1.
The results demonstrate that the H7N9 virus persisted in
sputum or tracheal aspirate specimens for an average of
6.14 days, while the virus persisted in throat swab samples
for 2.42 days.
Discussion
In March 2013, the novel reassortant avian influenza A
(H7N9) virus firstly occurred in three persons in Shang-
hai of China, and then more and more peoples were
killed by the novel virus that had been found in ducks,
chickens and birds. Until Jul 31, 2014, 413 infections
and 157 deaths by the novel H7N9 virus were reported
in China. Additionally, several family clusters of avian
influenza A (H7N9) virus infection were reported during
the outbreak of this virus in China [12]. Most of the
cases of novel avian H7N9 infections reported were viru-
lent, and the deaths resulted from the rapid development
of severe pneumonia and acute respiratory distress syn-
drome (ARDS) [11,12,15-19].
Tissue culture is the “gold standard” for the diagnosis
of viral respiratory infections. However, PCR is signifi-
cantly more sensitive and highly specific for the detec-
tion of respiratory viruses. Therefore, research into PCR
techniques for detecting viral infections is conducted in
many laboratories [1,2]. There is an urgent need to de-
velop a rapid and specific molecular test for the early
Table 3 Performance of multiplex PCR in comparison to
tissue culture for 130 clinical specimens
Virus
Culture Multiplex WHO Sens.
M/W
Spec.
M/W+ - + - + -
FluA 13a 117 15 115 15 115 100/100 98.3/98.3
H7 4 126 4 126 4 126 100/100 100/100
N9 4 126 4 126 4 126 100/100 100/100
Sens., sensitivity; Spec., specificity; M/W, Multiplex/WHO. Values refer
individually to the virus culture.
aTwo negative samples by tissue culture consisted of one H1N1 (2009) and
one H3N2 virus by genomic sequence analysis. Indeterminate results were
excluded from sensitivity and specificity calculations.
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detection and confirmation of the novel avian influenza
A (H7N9) virus. In the earlier periods of the outbreaks
of this virus, one real-time RT-PCR method, recom-
mended by the WHO, was promptly announced for the
detection of novel influenza A (H7N9) viruses [13].
Subsequently, additional real-time RT-PCR methods
for the detection of avian influenza A (H7N0) were pub-
lished as the virus emerged in China [14,19-24]. These
methods were only applied to the analysis of the H7 and
N9 genes of the H7N9 virus and did not include the M
gene, which aids in the determination of novel H7N9 vi-
ruses. Nor did they use the RP gene, which can be used
as a control to monitor the quality of clinical samples to
ensure accurate results [1,2]. Additionally, the sequences
of the primers recommended by the WHO contained
slight discrepancies from those found in publicly avail-
able gene databases of novel H7N9 viruses isolated from
human cases. Thus, the M, H, and N primer sets in the
WHO protocol do not exactly match the sequences of
the novel H7N9 virus (Table 1) [13]. For example, the
6th base of the FluA reverse primer was changed from
“G” to “A”, the 3rd base of the H7 reverse primer was al-
tered from “C” to “T”, and the 2nd and 23rd bases of the
N9 forward primer and the 19th base of the N9 reverse
primer were altered from “T” to “G”, “T” to “G”, and “A”
to “G”, respectively, relative to the novel H7N9 se-
quences. These errors may adversely affect viral detec-
tion in clinical specimens. Therefore, the nucleotide
sequences of primers and probes should be modified ac-
cording to the variation of novel influenza virus H7N9
sequences.
In our study, a multiplex real-time RT-PCR assay was
developed to simultaneously detect universal FluA strains,
as well as the novel H7N9 virus, in one reaction tube. The
primers and probes in the multiplex assay were designed
using the Influenza Primer Design Resource. The H7 and
N9 primers and probes exactly match the sequences of
the novel high virulent H7N9 virus for humans and low
pathogenic avian H7N9 virus, and the FluA primers and
probes completely match the M gene of most FluA viruses
using base degeneracy rules (Table 1). For example, the
6th base of the H7 forward primer and 15th base of the
H7 reverse primer are “R”, indicating “A” or “G”, and the
5th, 23rd and 26th bases of the H7 probe are “R”, “Y” and
“Y”, which indicate “A” or “G”, “C” or “T” and “C” or “T”,
respectively. These changes contribute to the reliable de-
tection of the virus by a PCR assay.
To confirm its sensitivity and specificity, the multiplex
real-time RT-PCR assay was compared to the WHO-
recommended assay. The limits of detection of the H7
and FluA genes, with respect to the detection of novel
H7N9 viruses and related RNA transcripts, did not sig-
nificantly differ between the two assays. The Ct values
for the amplification of the H7, N9, and FluA genes were
generally uniform in the multiplex assay, and were similar
to the Ct values of the CNIC H7 and CNIC FluA primers
used in the WHO protocol. Additionally, the sensitivity
and specificity of the multiplex assay, with respect to
FluA, H7, and N9, were equivalent to those of the WHO
protocol; no cross-reactions were observed with other vi-
ruses and pathogens.
Since March 2013, the National Health and Family
Planning Commission of the People’s Republic of China
has paid great attention to the increasing number of
H7N9 cases and has taken several measures, including
specimen testing, clinical treatments, epidemiological in-
vestigations, and medical observations of close contacts.
The surveillance of pneumonia cases of unknown origin
and influenza-like illness with consecutive days of high
fever (>38°C) and a history of close contact with poultry
has also been strengthened to detect the novel H7N9
virus.
The multiplex real-time RT-PCR assay and the real-
time RT-PCR assay recommended by the WHO were
used to detect, in parallel, the presence of the H7N9




Flu A H7 N9 RP Flu A H7 N9 RP
20130405-5 24.26 ± 0.35a 24.45 ± 0.21 25.03 ± 0.3 20.83 ± 0.3 24.77 ± 0.31 25.07 ± 0.15 24.85 ± 0.5 21.03 ± 0.3
20130406-32 26.43 ± 0.21 26.32 ± 0.31 26.23 ± 0.36 22.48 ± 0.35 26.43 ± 0.26 25.98 ± 0.15 26.52 ± 0.26 22.23 ± 0.15
20130407-69 20.15 ± 0.3 20.37 ± 0.32 20.7 ± 0.4 24.23 ± 0.32 19.78 ± 0.35 20.68 ± 0.36 20.07 ± 0.21 23.66 ± 0.31
20130409-92 31.33 ± 0.26 30.65 ± 0.36 31.23 ± 0.32 26.72 ± 0.4 30.85 ± 0.31 31.04 ± 0.5 31.2 ± 0.32 26.17 ± 0.25
aCt (cycle threshold) mean value ± SD.
Table 5 Comparison of the multiplex assay and WHO






(%)+ - + -
FluA 192a 819 192a 819 100 100
H7 35 976 35 976 100 100
N9 35 976 32b 979 91.4 100
RP 1011 0 1011 0 100 100
aInfluenza A (FluA) virus positive specimens, including H7N9.
bThree specimens with negative N9 and positive H7.
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virus in 1,011 clinical specimens, and 35 patients with
the novel H7N9 virus were found. The positive results of
the multiplex real-time RT-PCR assay were generally in
accordance with that of the real-time RT-PCR assay in
the WHO protocol. As previously noted, the Ct values
for the amplification of the H7, N9, FluA and RP genes
in the two assays were generally similar. In an addition,
the Ct values for RP gene assessed by both assays were low
with 18.5 to 29.8 in these clinical specimens, which indi-
cated good qualities of clinical specimens. A reliable qual-
ity of clinical specimens is important for the determination
of the result, and negative result of it has an effect on the
assay of objective result in some clinical specimens.
Interestingly, the WHO protocol resulted in three in-
determinate results with respect to the detection of the
N9 gene. These samples were subsequently considered
positive based on genomic DNA sequencing, and sam-
ples of the three cases were positive when the sputum
was re-collected and re-tested, respectively, so that their
mischaracterization was factored into the sensitivity and
specificity calculations. We suggest that the use of mis-
matched primers and probes, as well as extremely low
viral concentrations, may have led to this discrepancy.
The samples of uncertain results should be re-collected
and re-tested, which were significant for the determin-
ation of the results.
Different clinical specimens from the 35 hospitalized
patients with laboratory-confirmed H7N9 infections
were tested with the two assays. The results showed that
the multiplex assay and the WHO-recommended assays
did not significantly differ in their ability to detect H7N9
viruses; only one positive fecal sample detected by the
multiplex assay was negative using the WHO protocol.
Remarkably, the percentage of positive sputum or tracheal
aspirate specimens (100%) was higher than that of the
throat swabs samples (71.43%) on the first day after
hospital admission, and the average number of days that
patients’ sputum or tracheal aspirate samples tested posi-
tive for H7N9 viruses (mean value =6.14 days) was sig-
nificantly greater than that of the patients’ throat
swabs samples (mean value =2.42 days). This may re-
sult from the ability of the novel reassortant H7N9 virus
to easily infect human lung tissue, which leads to severe
pneumonia [10,11,15-18].
Figure 1 Surveillance of novel H7N9 viruses from the patients by multiplex real-time RT-PCR. The average number of days that patients
tested positive for H7N9 viruses in sputum or tracheal aspirates specimens (mean value =6.14 days) were significantly greater than that for
patients’ throat swabs samples (mean value =2.42 days).
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These results indicate that the multiplex assay de-
signed in this study is sufficiently sensitive and specific
to be used for the detection of the novel H7N9 virus.
Moreover, in comparison with a single real-time RT-
PCR assay, the merits of the multiplex real-time RT-PCR
assay applied in our study include the rapid detection
and discrimination of human FluA, and novel avian
H7N9 viruses using H7 and N9 gene-specific primers
in a single tube, which significantly simplifies the experi-
mental procedures and notably reduces experimental
expenses.
Conclusion
In summary, a sensitive and specific multiplex real-time
RT-PCR assay was developed for the early detection of the
novel reassortant H7N9 virus in patients. This assay will
enable the timely evaluation of antiviral pharmaceutical
therapies and other therapeutic interventions in the near
future. The multiplex RT-PCR assay will be of great im-
portance for public health officials during viral outbreaks.
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